Therapeutic immunostimulating effects of plant mitogens exemplified by the L4 isolectin of PHA.
A sizable body of evidence has accumulated showing that the characteristics of certain plant mitogens should endow them with valuable immunomodulating effects. Immune stimulation would be the fundamental function operating through the broad consequences of nonspecific T cell activation following binding with their CD3 or CD2 molecules. Based on in vitro evidences that PHA, operating through the LDCC pathway, might kill any tumor target if it remains present in adequate concentration, the administration of mitogens for cancer therapy would be rational, and the same mechanism should also justify these agents for treatment of certain infections. Being nonerythroagglutinating, although leukoagglutinating in higher concentrations, PHA-L4 serves as a suitable model for immunostimulating activities of the mitogens that can be applied directly or as in vitro activators of adoptive leukocytes. The PHA skin test can be utilized to gauge the serum levels of inhibitory glycoproteins that become elevated in a number of the disorders treatable by the mitogen, thus facilitating necessary dosage modifications. While PHA is the only mitogenic lectin that has been tested clinically, Con A and PWM are the two most widely studied among the alternatives, with others also available and many undoubtedly awaiting discovery. The development of practical methods for producing industrial quantities of nonagglutinating mitogens in pure form should be the goal, and accomplishing the latter might also answer certain hypersensitivity concerns.